Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and period: This unaudited report covers the three months ended December 31, 2019, Citius’s first fiscal quarter of 2020. The company is a development-stage specialty pharmaceutical business with no product revenue to date. Its candidates include Mino-Lok, Mino-Wrap and Halo-Lido.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2019 | Prior-year period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.665 million | $2.113 million |
| General and administrative expense | $1.563 million | $1.588 million |
| Total operating expenses / operating loss | $4.448 million | $3.872 million |
| Net loss | $4.322 million | $3.875 million |
| Basic and diluted loss per share | $0.15 | $0.22 |
| Cash used in operating activities | $5.114 million | $2.159 million |
Research and development spending rose 26%, mainly due to increased costs for Halo-Lido and Mino-Lok. The net loss increased by $448,000; a $110,207 FDA fee refund and higher interest income partially offset operating costs. No operating margin is meaningful because the company reported no revenue.
At December 31, 2019, cash and cash equivalents were $2.780 million, down from $7.894 million at September 30, 2019. Working capital was negative $794,467. Total liabilities were $4.606 million, including $172,970 of related-party notes payable and $1.122 million of operating lease liabilities. The company reported an accumulated deficit of $60.142 million.
Changes, outlook and material items
- Compared with the prior-year quarter, operating cash use more than doubled, R&D expense increased by $551,445, and net loss rose by $447,640. G&A expense decreased slightly.
- The company said the Mino-Lok Phase 3 trial would proceed following a positive interim futility analysis at 40% enrollment. Topline data from a subsequent interim efficacy analysis was expected in the first half of 2020. Management expected R&D expenses to continue increasing as it advanced Mino-Lok and began Mino-Wrap work.
- The filing identifies substantial doubt about the company’s ability to continue as a going concern. It reports no operating revenue, negative operating cash flow and a working-capital deficit, and says additional financing is needed. Management’s plans included equity financing and additional related-party borrowing, with no assurance funding would be available on acceptable terms.
- The cash-runway statements are not consistent: the going-concern note estimates resources would fund operations into the third quarter of fiscal 2020, while MD&A says cash at quarter-end plus January warrant proceeds were expected to fund operations only through March 2020. January 2020 warrant exercises generated $1.013 million in net proceeds.
- The company recorded a $110,207 FDA refund as other income. It adopted the new lease standard on October 1, 2019, recording a $1.138 million right-of-use asset and corresponding lease liability at adoption.
- In January 2020, Nasdaq notified the company that it had regained compliance with the $1.00 minimum bid-price requirement. Stockholders approved a new incentive plan in February authorizing up to 3.11 million shares.
- Equity dilution is a consideration: 24.417 million warrants were outstanding at quarter-end, in addition to 2.752 million outstanding stock options. The company reported no legal proceedings and no change to its previously disclosed risk factors.
Most important facts for investors to verify
- Current cash runway and subsequent financing, especially given the inconsistent runway estimates and the going-concern warning.
- Progress, safety and efficacy results for the Mino-Lok Phase 3 trial, including timing of the anticipated interim data.
- Development plans, costs and regulatory pathways for Mino-Wrap and Halo-Lido.
- Potential dilution from outstanding warrants, options and the newly approved 2020 stock plan.
- Whether future capital can be raised in sufficient amounts and on acceptable terms to fund operations and clinical development.